Dr. Mu has 20 years of industry experience in new drug development at global contract research organizations and pharmaceutical companies, and held management positions at WuXi AppTec, Lexicon Pharmaceuticals, and Covance.  He has led and contributed to various pharmaceutical development programs, ranging from IND to successful NDA.  He has licensed technologies from various organizations and raised federal, state, and venture financing.  Dr. Mu received a PhD in Toxicology at North Carolina State University and an MBA in Life Sciences at the Johns Hopkins University.

Dr. Altman is an investor, entrepreneur and leader of large and small scientific organizations.  His experiences include senior management positions at Beckman Coulter, Sequoia Pharmaceuticals, and Sandstone Diagnostics as well as advisor to GE Healthcare, Terumo-CaridianBCT and GenVec among others. He earned a PhD in biochemistry/virology and held an NSF Post-Doctoral Fellowship in the BioPhysics and McArdle Laboratories at the University of Wisconsin, Madison. 

Ronald V. Keech Professor of Pediatric Genetic Eye Disease Research, University of Iowa. PI on ocular gene therapy trials, including Luxturna.

Dina J Schrage Professor of Macular Degeneration Research, University of Iowa. Retinal Surgeon on ocular gene therapy trials, including Luxturna.

Professor of Ophthalmology, Chair, Ophthalmology, Oregon Health & Science University.  Retinal Surgeon on ocular gene therapy trials.

Chief Ophthalmic Genetics Division, Martha and Eddie Peterson Endowed Professor, Oregon Health & Science University.  PI on ocular gene therapy trials.